MAGEA4 and cancer: We further studied the association between the subtypes and the expression of 12 potentially targetable immune checkpoint genes, which were selected based on current inhibitor drugs in clinical trials or drugs approved for specific cancer types, and the results indicated remarkable differences in the expression of these genes between the three subtypes, except for FGL1, CTAG1B and MAGEA4 (Figure 3C).